《美国内科医师学会杂志俱乐部》。持续雄激素剥夺疗法增加了老年前列腺癌男性患糖尿病和脆性骨折的风险。 - Suppr | 超能文献

ACP Journal Club. Continuous androgen-deprivation therapy increased risk for diabetes and fragility fractures in older men with prostate cancer.

作者信息

Hajdenberg Julio

机构信息

Anderson Cancer Center Orlando, Orlando, Florida, USA.

出版信息

Ann Intern Med. 2009 Dec 15;151(12):JC6-14. doi: 10.7326/0003-4819-151-12-200912150-02014.

DOI:10.7326/0003-4819-151-12-200912150-02014

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

ACP Journal Club. Continuous androgen-deprivation therapy increased risk for diabetes and fragility fractures in older men with prostate cancer.《美国内科医师学会杂志俱乐部》。持续雄激素剥夺疗法增加了老年前列腺癌男性患糖尿病和脆性骨折的风险。

Ann Intern Med. 2009 Dec 15;151(12):JC6-14. doi: 10.7326/0003-4819-151-12-200912150-02014.

2

Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men.雄激素剥夺治疗的前列腺癌男性骨折类型和风险因素：19079 名男性的匹配队列研究。

J Urol. 2010 Sep;184(3):918-23. doi: 10.1016/j.juro.2010.04.068.

3

ACP Journal Club. Intermittent and continuous androgen deprivation did not differ for mortality after radiotherapy for prostate cancer.《美国内科医师学会杂志俱乐部》。对于前列腺癌放疗后的死亡率，间歇性雄激素剥夺和持续性雄激素剥夺并无差异。

Ann Intern Med. 2013 Jan 15;158(2):JC9. doi: 10.7326/0003-4819-158-2-201301150-02009.

4

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.托瑞米芬降低接受雄激素剥夺治疗的前列腺癌男性骨折风险。

J Urol. 2013 Jan;189(1 Suppl):S45-50. doi: 10.1016/j.juro.2012.11.016.

5

ACP Journal Club. Review: Androgen deprivation therapy does not increase CV mortality in prostate cancer.《美国内科医师学会杂志俱乐部》。综述：雄激素剥夺疗法不会增加前列腺癌患者的心血管死亡率。

Ann Intern Med. 2012 Apr 17;156(8):JC4-04, JC4-05. doi: 10.7326/0003-4819-156-8-201204170-02004.

6

ACP Journal Club. Radiation plus androgen deprivation therapy reduced mortality in locally advanced prostate cancer.《美国内科医师学会杂志俱乐部》。放疗联合雄激素剥夺疗法可降低局部晚期前列腺癌的死亡率。

Ann Intern Med. 2012 Apr 17;156(8):JC4-05, JC4-04. doi: 10.7326/0003-4819-156-8-201204170-02005.

7

Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.接受雄激素剥夺治疗的前列腺癌男性患代谢综合征、糖尿病和心血管疾病的风险增加。

Pharmacotherapy. 2008 Dec;28(12):1511-22. doi: 10.1592/phco.28.12.1511.

8

Impact of androgen deprivation therapy on weight gain differs by age in men with nonmetastatic prostate cancer.雄激素剥夺疗法对非转移性前列腺癌男性体重增加的影响因年龄而异。

J Urol. 2012 Dec;188(6):2183-8. doi: 10.1016/j.juro.2012.08.018. Epub 2012 Oct 18.

9

The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.双膦酸盐在接受雄激素剥夺治疗的前列腺癌男性患者中的作用。

Oncology (Williston Park). 2004 May;18(5 Suppl 3):21-5.

10

Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.与前列腺癌、雄激素剥夺治疗及骨并发症相关的医疗保健费用。

J Urol. 2007 Oct;178(4 Pt 1):1423-8. doi: 10.1016/j.juro.2007.05.135. Epub 2007 Aug 16.

引用本文的文献

1

Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis.雄激素剥夺疗法与糖尿病有关：荟萃分析证据。

J Diabetes Investig. 2016 Jul;7(4):629-36. doi: 10.1111/jdi.12472. Epub 2016 Feb 8.